KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments (2016 - 2019)

Esperion Therapeutics filings provide 3 years of Long-Term Investments readings, the most recent being $733000.0 for Q1 2019.

  • On a quarterly basis, Long-Term Investments fell 98.27% to $733000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $733000.0, a 98.27% decrease, with the full-year FY2018 number at $243000.0, down 99.67% from a year prior.
  • Long-Term Investments hit $733000.0 in Q1 2019 for Esperion Therapeutics, up from $243000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $73.4 million in Q4 2017 to a low of $243000.0 in Q4 2018.
  • Median Long-Term Investments over the past 3 years was $13.4 million (2018), compared with a mean of $23.9 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 99.67% in 2018 and later crashed 98.27% in 2019.
  • Esperion Therapeutics' Long-Term Investments stood at $73.4 million in 2017, then plummeted by 99.67% to $243000.0 in 2018, then soared by 201.65% to $733000.0 in 2019.
  • The last three reported values for Long-Term Investments were $733000.0 (Q1 2019), $243000.0 (Q4 2018), and $5.2 million (Q3 2018) per Business Quant data.